table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ...
ruxolitinib Cao
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...

3 studies excluded by filtering options 0

6490 Kaplanski, 2020 0300selection pending
6714 DEVENT, 0 110risk of bias not avaialble
9239 Tziolos, 2021 1130not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons